arrow
C

Christophe Dooms

KU Leuven
H指数:51
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib
2025-12-200
PRE
Lung Volume Reduction Surgery for Cannabis-Associated Emphysema: Expanding Indication With Functional and Quality of Life Improvements

大麻相关性肺气肿的肺减容手术:基于功能和生活质量改善的适应证扩展

2025-12-010
PRE
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study

Amivantamab-化疗在EGFR外显子20插入的非小细胞肺癌中的应用:来自III期PAPILLON研究的治疗交叉和其他终点的影响

2025-11-030
OAAI
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary
2025-03-010
OAAI
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Amivantamab联合lazertinib与osimertinib治疗具有高危疾病生物标志物的一线EGFR突变晚期非小细胞肺癌: 来自MARIPOSA的二次分析

2024-09-015
OAAI
Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC

Sotorasib (960 mg或240 mg) 每天一次用于先前接受过KRAS治疗的晚期NSCLC患者G12C-mutated

2024-09-012
PRE
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

在早期非小细胞肺癌患者中,新辅助派姆单抗加化疗后辅助派姆单抗与单独新辅助化疗的比较 (KEYNOTE-671): 一项随机,双盲,安慰剂对照的3期试验

LANCET
IF88.5
2024-09-014
PRE
Implementation of an enhanced recovery protocol for lung volume reduction surgery: an observational cohort study
2024-03-201
OA
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

罗索替尼在ROS1融合阳性非小细胞肺癌中的应用

2024-01-1118
PRE
Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary

sotorasib对KRAS G12C-mutated非小细胞肺癌患者的长期益处: 简明语言总结

2023-11-271
OA
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

围手术期Pembrolizumab治疗早期非小细胞肺癌

2023-08-10367
PRE
Sotorasib versus docetaxel for previously treated non-small- cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Sotorasib与多西他赛治疗KRASG12C突变的非小细胞肺癌: 一项随机,开放标签,3期试验

LANCET
IF88.5
2023-03-01219
OAAI